Research We Built On

Landmark foundational study. First paper to identify UA as a direct mitophagy inducer. Demonstrated lifespan extension in worms and improved grip strength and endurance in aged mice — establishing the mechanistic rationale for the entire compound class.

First-in-human RCT. 100 healthy middle-aged adults. UA supplementation upregulated 211 genes linked to mitochondrial biogenesis and autophagy flux vs. placebo. Confirmed safety and tolerability across all dose arms (250 mg–2000 mg).

Pivotal Phase II RCT. 88 older adults over 4 months. UA supplementation significantly improved hand-grip strength, VO2 max, and mitochondrial gene expression. First human evidence of functional muscle benefit from a mitophagy activator.

UA attenuated β-amyloid accumulation and restored spatial memory in 5xFAD mice via autophagy-mediated plaque clearance. Highlights potential neuroprotective properties beyond skeletal muscle, relevant to longevity phenotypes.

UA supplementation restored tight-junction protein expression and reduced LPS translocation in aged mice. Proposes gut barrier integrity as a primary longevity mechanism — mechanistically upstream of systemic inflammation reduction.

Largest UA RCT to date. 139 active adults aged 65–90. Statistically significant improvement in 6-minute walk test, mitochondrial DNA copy number, and plasma mtDNA quality markers vs placebo. Strongest human efficacy signal to date.

Oral UA supplementation in aged mice reversed a 60% decline in mitophagy flux in skeletal and cardiac muscle. Identifies the mitophagy–PINK1/Parkin pathway as the primary target, validating the mechanism in metabolically active tissues most relevant to sarcopenia.

Field-defining paper. Spermidine was shown to induce autophagy in yeast, flies, worms, and human cells through histone hypoacetylation. The first demonstration that a dietary polyamine directly engages the longevity autophagy axis across species.

Landmark cardiovascular study. Spermidine supplementation reduced cardiac aging and fibrosis, lowered blood pressure, and extended lifespan in aged mice — via autophagy-dependent protection of cardiomyocytes. Human epidemiological data corroborated cardiovascular benefit.

Bruneck cohort of 829 adults followed for 20 years. Highest tertile of dietary spermidine intake was associated with a 40% reduction in cardiovascular mortality and significantly lower all-cause mortality — dose-dependent relationship after full adjustment.

100 older adults with subjective cognitive decline. 3 months of spermidine (1.2 mg/day) produced statistically significant improvements on mnemonic discrimination tasks and recall indices. First human cognitive RCT for spermidine.

Resolves the eIF5A–hypusination axis as spermidine's primary molecular mechanism, explaining why standard autophagy inducers produce weaker mitochondrial selectivity. Opens new understanding of spermidine's non-redundant role in mitophagy regulation.

Comprehensive review mapping spermidine's roles in epigenetic regulation, mitochondrial proteostasis, inflammation, and senescence clearance. Provides the systems-level framework linking spermidine to multi-hallmark aging biology across 12 model organisms.

Spermidine supplementation delayed CD4+ and CD8+ T-cell senescence markers in aged mice and human PBMCs ex vivo, reducing p21/p16 expression. Positions spermidine as an immunosenescence modulator — directly relevant to longevity phenotype reversal.

Double-blind RCT in 79 hypertensive patients. Aged garlic extract (containing standardised SAC) reduced systolic BP by 10.2 ± 4.3 mmHg vs placebo over 12 weeks — comparable to first-line antihypertensive dose reduction. No adverse events.

SAC at physiologically relevant concentrations suppressed NF-κB activation, reduced IL-6 and TNF-α secretion, and restored endothelial nitric oxide synthase expression in ox-LDL-stimulated HUVECs — mechanistically linking SAC to plaque stability and vasodilation.

SAC reduced Aβ1–42-induced ROS by 62%, restored mitochondrial membrane potential, and improved Morris water maze performance in SAMP8 aged mice. Mechanistically identifies Nrf2 pathway activation as SAC's neuroprotective route.

8 weeks of SAC supplementation reversed histological steatosis scores, normalised ALT/AST, and reduced hepatic triglyceride content in a high-fat-diet NAFLD model. Upregulation of AMPK and PPAR-α identified as the dominant metabolic mechanism.

SAC reaches peak plasma concentration within 1.5 h with near-complete oral bioavailability (~98%) — significantly superior to allicin or alliin. Half-life of ~10 h enables consistent tissue exposure from a single daily dose. Critical PK data supporting once-daily M3 dosing.

SAC concurrently activated Nrf2-driven antioxidant genes and suppressed NLRP3 inflammasome activation in macrophages — providing a dual anti-inflammatory mechanism relevant to inflammaging and metabolic disease in the longevity context.